Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

AI drug discovery

  • Home
  • AI drug discovery
Rentosertib: The First AI-Discovered TNIK Inhibitor Shows Promise in Idiopathic Pulmonary Fibrosis Phase 2a Trial
Posted inAllergy & Immunology Clinical Updates news Respiratory Specialties

Rentosertib: The First AI-Discovered TNIK Inhibitor Shows Promise in Idiopathic Pulmonary Fibrosis Phase 2a Trial

Posted by MedXY By MedXY 08/27/2025
Rentosertib, an AI-designed TNIK inhibitor, demonstrated safety and preliminary efficacy in idiopathic pulmonary fibrosis in a randomized phase 2a trial, marking a milestone in AI-driven drug development for progressive lung diseases.
Read More
  • The Economic Burden of Gestational Diabetes and Body Mass Index Changes Between Pregnancies: A Retrospective Cohort Study
  • Assessing Uterine Scar Healing After Consecutive Cesareans: Insights from Sonohysterography on Endometrium-Free Closure Technique
  • Enhanced Prenatal Care Models in Low-Income Latine Populations: Impact on Care Experience in a Randomized Trial
  • Endothelial-to-Mesenchymal Transition: Unlocking New Therapeutic Avenues for Portal Vein Thrombosis in Cirrhosis
  • International Consensus on Measuring and Repairing the Gut Barrier in IBD: Practical guidance for clinical trials
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in